Home / Intelligence /

Search

Webinars

Enabling Contracting Capabilities: Uncovering the What, When and How

Available On Demand

Is your company planning to begin commercial contracting or preparing to contract within a new channel? If you are a leader in a pre-commercial or commercial emerging life sciences company facing these challenges, this webinar is designed for you. Join our experts from TGaS Advisors, a division of Trinity Life Sciences, as we share what you need to know whether you are embarking on your commercial contracting journey or thinking about a new contracting channel such as payer contracting, provider…

Watch Now

Webinars

Valuing an Early-Stage Asset in Pharma and Biotech: Innovative Approaches for Novel Therapies

Available On Demand

Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets. Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…

Watch Now

White Papers

Smarter Commercialization Investment for First Launch Biopharma

With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…

Read Now

White Papers

Valuing an Early-Stage Asset in Pharma and Biotech

In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…

Read Now

Briefs

A Playbook for Optimizing Your Commercial Data Environment

What is keeping commercial data leaders in emerging life sciences companies up at night as they bring their technology to life in preparation for launch? What are the biggest concerns when considering changes to an existing infrastructure? Trinity Life Sciences has partnered with many first launch and emerging companies for decades to find solutions to their biggest technology challenges. In this Advisory Brief, we pause to reflect upon some of the common missteps we’ve seen companies take when deploying their…

Read Now

Case Studies

Early P&MA Forecasting Support for a Pipeline Asset

Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research. Geographic Scope: Client Situation The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization. Trinity’s Solution Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting…

Read Now

Webinars

Building Commercial Teams

Available On Demand

Watch our webinar recording of Curt Staab, Sr. Vice President of Emerging Life Sciences Network as he draws from the latest landscape findings about how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the pandemic. We explore how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the COVID-19 pandemic. By submitting this form, creating an account, and/or using our website (or using…

Watch Now

Briefs

Making the Leap From Pharma to Pre-Commercial: A Field Guide for the New CCO

By Curt Staab, TGaS® Advisors, a division of Trinity Executive Summary TGaS® Advisors’ Emerging Life Sciences Network (elsN) has gathered advice and lessons learned from a broad-based CCO peer network to create this guide, the first in a series designed to help CCOs manage day-to-day and for the long-term. In this White Paper, we provide an overview of a CCO’s responsibilities, resources and expectations. Future issues will offer advice from peers and experts on launch planning and hiring. To learn more,…

Read Now

White Papers

How to Approach Asset Valuation in Pharma & Biotech:

Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…

Read Now